The Forbes article glosses over the tremendous amount of work needed to move a candidate that works on cells in a dish (or a mouse) through clinical trials and into something that can be picked up at CVS.

These are hard—-and capital-intensive—things in their own right—it’s not like Apple snapping up your an app and adding it to the next iOS release.